Fiserv earnings missed by $0.61, revenue fell short of estimates
Investing.com - H.C. Wainwright reiterated its Buy rating and $56.00 price target on LENZ Therapeutics Inc (NASDAQ:LENZ), currently trading at $31.97, as the company prepares for the fourth-quarter launch of its presbyopia eye drop treatment VIZZ. The target represents a 75% upside from current levels, with analyst targets ranging from $36 to $67.
Analyst Matthew Caufield maintained the rating after conducting interviews with key opinion leaders (KOLs) in ophthalmology to gauge market receptivity for VIZZ (aceclidine ophthalmic solution, 1.44%), which recently received FDA approval. According to InvestingPro data, LENZ maintains a "Good" Financial Health score of 2.66, with strong liquidity metrics supporting its commercialization plans.
The research focused on specialists whose practices include a significant proportion of presbyopia patients currently using reading glasses, who have experience with the first FDA-approved eye drop for the condition (VUITY), and who could provide insight on patient demand for VIZZ as an alternative to traditional reading glasses.
H.C. Wainwright’s analysis covered optimal patient profiles, expectation management, receptivity among both specialists and patients, and strategies for navigating the presbyopia treatment landscape.
The firm noted that these recent KOL perspectives align with and support their previous analysis conducted before VIZZ received FDA approval, reinforcing their positive outlook on LENZ Therapeutics as the product enters its commercial launch phase in the fourth quarter of 2025. The company’s stock has shown strong momentum, with a 42% gain over the past six months. Discover more detailed insights and 8 additional ProTips for LENZ with an InvestingPro subscription.
In other recent news, LENZ Therapeutics has announced the launch of its presbyopia treatment, VIZZ, in the United States. This new product, an aceclidine ophthalmic solution, is now being distributed to eye care professionals, with consumer shipments set to begin in October and broader retail availability expected by mid-fourth quarter of 2025. In addition to the product launch, LENZ Therapeutics has completed a block trade, selling 1,748,634 shares of its common stock at $45.75 per share, resulting in gross proceeds of approximately $80 million.
The company has also seen positive movement in analyst ratings, with Piper Sandler raising its price target for LENZ Therapeutics to $67, maintaining an Overweight rating, and H.C. Wainwright increasing its price target to $56 while keeping a Buy rating. These updates follow the FDA approval of VIZZ, which has been identified by H.C. Wainwright as one of its top picks for the second half of 2025. The recent developments reflect the company’s strategic efforts to strengthen its market position and financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.